NEW YORK (GenomeWeb News) – BioFocus will use its screening technologies and compound collections to find new hit compounds against key targets of interest for Barcelona, Spain-based pharmaceutical firm Almirall under a new agreement announced today.
Almirall said that BioFocus will help it find new hit compounds against key targets as possible treatments for respiratory and inflammatory conditions.
BioFocus has three research centers in the UK, Switzerland, and the Netherlands.
The Spanish drug developer focuses its efforts on asthma, COPD, gastrointestinal disorders, psoriasis, and other dermatological conditions.
Financial terms of the agreement were not released.